TokenPost·
Pfizer Candidate Shows Immune Response Across 25 Serotypes in Phase 2
25 serotypes
immune response coverage
A four-dose series of PF-07872412 was evaluated, with safety and tolerability also reported.
More news
- Crypto BriefingHouthis vow continued attacks on Saudi Arabia’s King Khalid airport
- TokenPostLighter Token Falls 1.6% to $3.21 in Saturday Market Snapshot
- TokenPostCrypto Market Cap Falls 3.65% to $2.71 Trillion in 24 Hours
- TokenPostFiredancer Requires a 1 SOL Burn for Every Bug Bounty Report
- CryptoSlateFiredancer makes bounty hunters burn 1 SOL even for duplicate bug reports
- NewsBTCKraken Parent Payward Wins In-Principle Approval For Kazakhstan Expansion